Cargando…

Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients

Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bae, Susie, Wong, Hui-Li, Tie, Jeanne, Desai, Jayesh, Field, Kathryn, Kosmider, Suzanne, Fourlanos, Spiros, Jones, Ian, Skinner, Iain, Gibbs, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436511/
https://www.ncbi.nlm.nih.gov/pubmed/26074965
http://dx.doi.org/10.1155/2015/189132
_version_ 1782372095557107712
author Bae, Susie
Wong, Hui-Li
Tie, Jeanne
Desai, Jayesh
Field, Kathryn
Kosmider, Suzanne
Fourlanos, Spiros
Jones, Ian
Skinner, Iain
Gibbs, Peter
author_facet Bae, Susie
Wong, Hui-Li
Tie, Jeanne
Desai, Jayesh
Field, Kathryn
Kosmider, Suzanne
Fourlanos, Spiros
Jones, Ian
Skinner, Iain
Gibbs, Peter
author_sort Bae, Susie
collection PubMed
description Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5–101.2). The diabetes patients (21.6%, n = 241) were older than nondiabetes patients (median 74.0 versus 69.6, p = 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%, p = 0.002) but were equally likely to complete treatment (69.7 versus 67.7%, p = 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71–1.63) or overall survival (HR = 1.23, 95% CI 0.88–1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer.
format Online
Article
Text
id pubmed-4436511
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44365112015-06-14 Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients Bae, Susie Wong, Hui-Li Tie, Jeanne Desai, Jayesh Field, Kathryn Kosmider, Suzanne Fourlanos, Spiros Jones, Ian Skinner, Iain Gibbs, Peter J Cancer Epidemiol Research Article Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5–101.2). The diabetes patients (21.6%, n = 241) were older than nondiabetes patients (median 74.0 versus 69.6, p = 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%, p = 0.002) but were equally likely to complete treatment (69.7 versus 67.7%, p = 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71–1.63) or overall survival (HR = 1.23, 95% CI 0.88–1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer. Hindawi Publishing Corporation 2015 2015-05-05 /pmc/articles/PMC4436511/ /pubmed/26074965 http://dx.doi.org/10.1155/2015/189132 Text en Copyright © 2015 Susie Bae et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Bae, Susie
Wong, Hui-Li
Tie, Jeanne
Desai, Jayesh
Field, Kathryn
Kosmider, Suzanne
Fourlanos, Spiros
Jones, Ian
Skinner, Iain
Gibbs, Peter
Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title_full Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title_fullStr Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title_full_unstemmed Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title_short Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients
title_sort impact of diabetes status and medication on presentation, treatment, and outcome of stage ii colon cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436511/
https://www.ncbi.nlm.nih.gov/pubmed/26074965
http://dx.doi.org/10.1155/2015/189132
work_keys_str_mv AT baesusie impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT wonghuili impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT tiejeanne impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT desaijayesh impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT fieldkathryn impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT kosmidersuzanne impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT fourlanosspiros impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT jonesian impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT skinneriain impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients
AT gibbspeter impactofdiabetesstatusandmedicationonpresentationtreatmentandoutcomeofstageiicoloncancerpatients